FOSTER CITY, Calif. / Aug 08, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2024 results of operations.
“Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “One of the key highlights of the quarter was interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapavir in HIV prevention for cisgender women. We look forward to additional clinical readouts in the coming months, and to potentially launching seladelpar for primary biliary cholangitis in the United States.”
Second Quarter 2024 Financial Results
Second Quarter 2024 Product Sales
Total second quarter 2024 product sales increased 5% to $6.9 billion, compared to the same period in 2023. Total product sales, excluding Veklury, increased 6% to $6.7 billion in the second quarter 2024, compared to the same period in 2023, primarily due to higher product sales in HIV, Liver Disease and Oncology.
HIV product sales increased 3% to $4.7 billion in the second quarter 2024, compared to the same period in 2023, primarily driven by higher demand across treatment and prevention, partially offset by lower average realized price due to channel mix.
The Liver Disease portfolio sales increased 17% to $832 million in the second quarter 2024, compared to the same period in 2023. This was primarily driven by higher average realized price due to channel mix in the United States, as well as higher demand in products for chronic hepatitis C virus (“HCV”), chronic hepatitis B virus (“HBV”) and, in Europe, chronic hepatitis D virus (“HDV”).
Veklury sales decreased 16% to $214 million in the second quarter 2024, compared to the same period in 2023, primarily driven by lower rates of COVID-19 related hospitalizations.
Cell Therapy product sales increased 11% to $521 million in the second quarter 2024, compared to the same period in 2023.
Trodelvy® (sacituzumab govitecan-hziy) sales increased 23% to $320 million in the second quarter 2024, compared to the same period in 2023, primarily driven by higher demand in second-line metastatic triple negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer.
Second Quarter 2024 Product Gross Margin, Operating Expenses and Effective Tax Rate
Guidance and Outlook
For the full-year 2024, Gilead expects:
(in millions, except per share amounts) |
| August 8, 2024 Guidance |
| |||||
| Low End | High End | Comparison to April 25, 2024 Guidance | |||||
Product sales |
| $ | 27,100 |
| $ | 27,500 |
| Unchanged |
Product sales, excluding Veklury |
| $ | 25,800 |
| $ | 26,200 |
| Unchanged |
Veklury |
| $ | 1,300 |
| $ | 1,300 |
| Unchanged |
Diluted EPS |
| $ | 0.00 |
| $ | 0.30 |
| Previously $0.10 to $0.50 |
Non-GAAP diluted EPS |
| $ | 3.60 |
| $ | 3.90 |
| Previously $3.45 to $3.85 |
Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2024 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.
Key Updates Since Our Last Quarterly Release
Virology
Oncology
Inflammation
Corporate
Certain amounts and percentages in this press release may not sum or recalculate due to rounding.
Conference Call
At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.
Non-GAAP Financial Information
The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its anticipated full year 2024 financial results, including as a result of the uncertainty of the amount and timing of Veklury revenues; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx and Arcus; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Biktarvy, Trodelvy, Truvada, Yescarta, bevacizumab, bictegravir, bulevirtide, anitocabtagene autoleucel, domvanalimab, etrumadenant, GS-1720, GS-4182, lenacapavir, teropavimab, seladelpar, zimberelimab, and zinlirvimab (such as the ARTISTRY-1, ASSURE, EDGE-Gastric, EVOKE-01, EVOKE-02, iMMagine-3, MYR201, MYR301, PURPOSE-1, TROPiCS-04, ZUMA-3 and ZUMA-24 studies) , and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, including FDA approval of the New Drug Application for seladelpar, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority (such as the risk that the FDA may not grant full approval or may withdraw its accelerated approval for Trodelvy for the treatment of locally advanced or metastatic urothelial cancer); Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies and may therefore be reluctant to prescribe the products, including Biktarvy; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June 30, 2024 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.
Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITETM, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. Other trademarks are the property of their respective owners.
For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions, except per share amounts) |
|
| 2024 |
|
|
| 2023 |
|
|
| 2024 |
|
|
| 2023 |
|
Revenues: |
|
|
|
|
|
|
|
| ||||||||
Product sales |
| $ | 6,912 |
|
| $ | 6,564 |
|
| $ | 13,559 |
|
| $ | 12,870 |
|
Royalty, contract and other revenues |
|
| 41 |
|
|
| 35 |
|
|
| 81 |
|
|
| 81 |
|
Total revenues |
|
| 6,954 |
|
|
| 6,599 |
|
|
| 13,640 |
|
|
| 12,951 |
|
Costs and expenses: |
|
|
|
|
|
|
|
| ||||||||
Cost of goods sold |
|
| 1,544 |
|
|
| 1,442 |
|
|
| 3,096 |
|
|
| 2,843 |
|
Research and development expenses |
|
| 1,351 |
|
|
| 1,407 |
|
|
| 2,871 |
|
|
| 2,854 |
|
Acquired in-process research and development expenses |
|
| 38 |
|
|
| 236 |
|
|
| 4,169 |
|
|
| 717 |
|
In-process research and development impairment |
|
| — |
|
|
| — |
|
|
| 2,430 |
|
|
| — |
|
Selling, general and administrative expenses |
|
| 1,377 |
|
|
| 1,849 |
|
|
| 2,752 |
|
|
| 3,168 |
|
Total costs and expenses |
|
| 4,309 |
|
|
| 4,934 |
|
|
| 15,317 |
|
|
| 9,581 |
|
Operating income (loss) |
|
| 2,644 |
|
|
| 1,665 |
|
|
| (1,678 | ) |
|
| 3,370 |
|
Interest expense |
|
| 237 |
|
|
| 230 |
|
|
| 491 |
|
|
| 459 |
|
Other (income) expense, net |
|
| 355 |
|
|
| (152 | ) |
|
| 265 |
|
|
| 22 |
|
Income (loss) before income taxes |
|
| 2,053 |
|
|
| 1,588 |
|
|
| (2,433 | ) |
|
| 2,888 |
|
Income tax expense |
|
| 438 |
|
|
| 549 |
|
|
| 123 |
|
|
| 865 |
|
Net income (loss) |
|
| 1,614 |
|
|
| 1,039 |
|
|
| (2,556 | ) |
|
| 2,024 |
|
Net loss attributable to noncontrolling interest |
|
| — |
|
|
| (6 | ) |
|
| — |
|
|
| (32 | ) |
Net income (loss) attributable to Gilead |
| $ | 1,614 |
|
| $ | 1,045 |
|
| $ | (2,556 | ) |
| $ | 2,055 |
|
Basic earnings (loss) per share attributable to Gilead |
| $ | 1.29 |
|
| $ | 0.84 |
|
| $ | (2.05 | ) |
| $ | 1.65 |
|
Shares used in basic earnings (loss) per share attributable to Gilead calculation |
|
| 1,247 |
|
|
| 1,249 |
|
|
| 1,247 |
|
|
| 1,249 |
|
Diluted earnings (loss) per share attributable to Gilead |
| $ | 1.29 |
|
| $ | 0.83 |
|
| $ | (2.05 | ) |
| $ | 1.63 |
|
Shares used in diluted earnings (loss) per share attributable to Gilead calculation |
|
| 1,251 |
|
|
| 1,258 |
|
|
| 1,247 |
|
|
| 1,260 |
|
|
|
|
|
|
|
|
|
| ||||||||
Supplemental Information: |
|
|
|
|
|
|
|
| ||||||||
Cash dividends declared per share |
| $ | 0.77 |
|
| $ | 0.75 |
|
| $ | 1.54 |
|
| $ | 1.50 |
|
Product gross margin |
|
| 77.7 | % |
|
| 78.0 | % |
|
| 77.2 | % |
|
| 77.9 | % |
Research and development expenses as a % of revenues |
|
| 19.4 | % |
|
| 21.3 | % |
|
| 21.0 | % |
|
| 22.0 | % |
Selling, general and administrative expenses as a % of revenues |
|
| 19.8 | % |
|
| 28.0 | % |
|
| 20.2 | % |
|
| 24.5 | % |
Operating margin |
|
| 38.0 | % |
|
| 25.2 | % |
|
| (12.3 | )% |
|
| 26.0 | % |
Effective tax rate |
|
| 21.4 | % |
|
| 34.6 | % |
|
| (5.1 | )% |
|
| 29.9 | % |
GILEAD SCIENCES, INC. TOTAL REVENUE SUMMARY (unaudited) | ||||||||||||||||||
|
| Three Months Ended |
|
|
| Six Months Ended |
|
| ||||||||||
|
| June 30, |
|
|
| June 30, |
|
| ||||||||||
(in millions, except percentages) |
|
| 2024 |
|
| 2023 |
| Change |
|
| 2024 |
|
| 2023 |
| Change | ||
Product sales: |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
HIV |
| $ | 4,745 |
| $ | 4,626 |
| 3 | % |
| $ | 9,088 |
| $ | 8,816 |
| 3 | % |
Liver Disease |
|
| 832 |
|
| 711 |
| 17 | % |
|
| 1,569 |
|
| 1,386 |
| 13 | % |
Oncology |
|
| 841 |
|
| 728 |
| 15 | % |
|
| 1,629 |
|
| 1,398 |
| 17 | % |
Other |
|
| 280 |
|
| 243 |
| 15 | % |
|
| 504 |
|
| 442 |
| 14 | % |
Total product sales excluding Veklury |
|
| 6,698 |
|
| 6,308 |
| 6 | % |
|
| 12,790 |
|
| 12,041 |
| 6 | % |
Veklury |
|
| 214 |
|
| 256 |
| (16 | )% |
|
| 769 |
|
| 829 |
| (7 | )% |
Total product sales |
|
| 6,912 |
|
| 6,564 |
| 5 | % |
|
| 13,559 |
|
| 12,870 |
| 5 | % |
Royalty, contract and other revenues |
|
| 41 |
|
| 35 |
| 18 | % |
|
| 81 |
|
| 81 |
| (1 | )% |
Total revenues |
| $ | 6,954 |
| $ | 6,599 |
| 5 | % |
| $ | 13,640 |
| $ | 12,951 |
| 5 | % |
GILEAD SCIENCES, INC. NON-GAAP FINANCIAL INFORMATION(1) (unaudited) | ||||||||||||||||||||
|
| Three Months Ended |
|
|
| Six Months Ended |
|
| ||||||||||||
|
| June 30, |
|
|
| June 30, |
|
| ||||||||||||
(in millions, except percentages) |
|
| 2024 |
|
|
| 2023 |
|
| Change |
|
| 2024 |
|
|
| 2023 |
|
| Change |
Non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Cost of goods sold |
| $ | 965 |
|
| $ | 861 |
|
| 12% |
| $ | 1,939 |
|
| $ | 1,732 |
|
| 12% |
Research and development expenses |
| $ | 1,335 |
|
| $ | 1,377 |
|
| (3)% |
| $ | 2,738 |
|
| $ | 2,816 |
|
| (3)% |
Acquired IPR&D expenses(2) |
| $ | 38 |
|
| $ | 236 |
|
| (84)% |
| $ | 4,169 |
|
| $ | 717 |
|
| NM |
Selling, general and administrative expenses |
| $ | 1,351 |
|
| $ | 1,848 |
|
| (27)% |
| $ | 2,646 |
|
| $ | 3,166 |
|
| (16)% |
Other (income) expense, net |
| $ | (37 | ) |
| $ | (83 | ) |
| (56)% |
| $ | (141 | ) |
| $ | (165 | ) |
| (15)% |
Diluted earnings per share attributable to Gilead |
| $ | 2.01 |
|
| $ | 1.34 |
|
| 50% |
| $ | 0.70 |
|
| $ | 2.71 |
|
| (74)% |
Shares used in non-GAAP diluted earnings per share attributable to Gilead calculation |
|
| 1,251 |
|
|
| 1,258 |
|
| (1)% |
|
| 1,254 |
|
|
| 1,260 |
|
| —% |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Product gross margin |
|
| 86.0 | % |
|
| 86.9 | % |
| -84 bps |
|
| 85.7 | % |
|
| 86.5 | % |
| -84 bps |
Research and development expenses as a % of revenues |
|
| 19.2 | % |
|
| 20.9 | % |
| -167 bps |
|
| 20.1 | % |
|
| 21.7 | % |
| -167 bps |
Selling, general and administrative expenses as a % of revenues |
|
| 19.4 | % |
|
| 28.0 | % |
| -857 bps |
|
| 19.4 | % |
|
| 24.4 | % |
| -504 bps |
Operating margin |
|
| 47.0 | % |
|
| 34.5 | % |
| NM |
|
| 15.7 | % |
|
| 34.9 | % |
| NM |
Effective tax rate |
|
| 17.8 | % |
|
| 21.0 | % |
| -322 bps |
|
| 51.4 | % |
|
| 20.0 | % |
| NM |
________________________________ | |
NM - Not Meaningful | |
(1) | Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below. |
(2) | Equal to GAAP financial information. |
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions, except percentages and per share amounts) |
|
| 2024 |
|
|
| 2023 |
|
|
| 2024 |
|
|
| 2023 |
|
Cost of goods sold reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP cost of goods sold |
| $ | 1,544 |
|
| $ | 1,442 |
|
| $ | 3,096 |
|
| $ | 2,843 |
|
Acquisition-related – amortization(1) |
|
| (579 | ) |
|
| (581 | ) |
|
| (1,158 | ) |
|
| (1,110 | ) |
Restructuring |
|
| — |
|
|
| — |
|
|
| 1 |
|
|
| — |
|
Non-GAAP cost of goods sold |
| $ | 965 |
|
| $ | 861 |
|
| $ | 1,939 |
|
| $ | 1,732 |
|
|
|
|
|
|
|
|
|
| ||||||||
Product gross margin reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP product gross margin |
|
| 77.7 | % |
|
| 78.0 | % |
|
| 77.2 | % |
|
| 77.9 | % |
Acquisition-related – amortization(1) |
|
| 8.4 | % |
|
| 8.8 | % |
|
| 8.5 | % |
|
| 8.6 | % |
Restructuring |
|
| (— | )% |
|
| — | % |
|
| (— | )% |
|
| — | % |
Non-GAAP product gross margin |
|
| 86.0 | % |
|
| 86.9 | % |
|
| 85.7 | % |
|
| 86.5 | % |
|
|
|
|
|
|
|
|
| ||||||||
Research and development expenses reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP research and development expenses |
| $ | 1,351 |
|
| $ | 1,407 |
|
| $ | 2,871 |
|
| $ | 2,854 |
|
Acquisition-related – other costs(2) |
|
| (3 | ) |
|
| (30 | ) |
|
| (70 | ) |
|
| (38 | ) |
Restructuring |
|
| (13 | ) |
|
| — |
|
|
| (63 | ) |
|
| — |
|
Non-GAAP research and development expenses |
| $ | 1,335 |
|
| $ | 1,377 |
|
| $ | 2,738 |
|
| $ | 2,816 |
|
|
|
|
|
|
|
|
|
| ||||||||
IPR&D impairment reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP IPR&D impairment |
| $ | — |
|
| $ | — |
|
| $ | 2,430 |
|
| $ | — |
|
IPR&D impairment |
|
| — |
|
|
| — |
|
|
| (2,430 | ) |
|
| — |
|
Non-GAAP IPR&D impairment |
| $ | — |
|
| $ | — |
|
| $ | — |
|
| $ | — |
|
|
|
|
|
|
|
|
|
| ||||||||
Selling, general and administrative expenses reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP selling, general and administrative expenses |
| $ | 1,377 |
|
| $ | 1,849 |
|
| $ | 2,752 |
|
| $ | 3,168 |
|
Acquisition-related – other costs(2) |
|
| (17 | ) |
|
| (1 | ) |
|
| (84 | ) |
|
| (2 | ) |
Restructuring |
|
| (8 | ) |
|
| — |
|
|
| (22 | ) |
|
| — |
|
Non-GAAP selling, general and administrative expenses |
| $ | 1,351 |
|
| $ | 1,848 |
|
| $ | 2,646 |
|
| $ | 3,166 |
|
|
|
|
|
|
|
|
|
| ||||||||
Operating income (loss) reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP operating income (loss) |
| $ | 2,644 |
|
| $ | 1,665 |
|
| $ | (1,678 | ) |
| $ | 3,370 |
|
Acquisition-related – amortization(1) |
|
| 579 |
|
|
| 581 |
|
|
| 1,158 |
|
|
| 1,110 |
|
Acquisition-related – other costs(2) |
|
| 21 |
|
|
| 31 |
|
|
| 153 |
|
|
| 40 |
|
Restructuring |
|
| 21 |
|
|
| — |
|
|
| 84 |
|
|
| — |
|
IPR&D impairment |
|
| — |
|
|
| — |
|
|
| 2,430 |
|
|
| — |
|
Non-GAAP operating income |
| $ | 3,265 |
|
| $ | 2,277 |
|
| $ | 2,148 |
|
| $ | 4,521 |
|
|
|
|
|
|
|
|
|
| ||||||||
Operating margin reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP operating margin |
|
| 38.0 | % |
|
| 25.2 | % |
|
| (12.3 | )% |
|
| 26.0 | % |
Acquisition-related – amortization(1) |
|
| 8.3 | % |
|
| 8.8 | % |
|
| 8.5 | % |
|
| 8.6 | % |
Acquisition-related – other costs(2) |
|
| 0.3 | % |
|
| 0.5 | % |
|
| 1.1 | % |
|
| 0.3 | % |
Restructuring |
|
| 0.3 | % |
|
| — | % |
|
| 0.6 | % |
|
| — | % |
IPR&D impairment |
|
| — | % |
|
| — | % |
|
| 17.8 | % |
|
| — | % |
Non-GAAP operating margin |
|
| 47.0 | % |
|
| 34.5 | % |
|
| 15.7 | % |
|
| 34.9 | % |
|
|
|
|
|
|
|
|
| ||||||||
Other (income) expense, net reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP other (income) expense, net |
| $ | 355 |
|
| $ | (152 | ) |
| $ | 265 |
|
| $ | 22 |
|
(Loss) gain from equity securities, net |
|
| (392 | ) |
|
| 69 |
|
|
| (405 | ) |
|
| (187 | ) |
Non-GAAP other (income) expense, net |
| $ | (37 | ) |
| $ | (83 | ) |
| $ | (141 | ) |
| $ | (165 | ) |
|
|
|
|
|
|
|
|
| ||||||||
Income (loss) before income taxes reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP income (loss) before income taxes |
| $ | 2,053 |
|
| $ | 1,588 |
|
| $ | (2,433 | ) |
| $ | 2,888 |
|
Acquisition-related – amortization(1) |
|
| 579 |
|
|
| 581 |
|
|
| 1,158 |
|
|
| 1,110 |
|
Acquisition-related – other costs(2) |
|
| 21 |
|
|
| 31 |
|
|
| 153 |
|
|
| 40 |
|
Restructuring |
|
| 21 |
|
|
| — |
|
|
| 84 |
|
|
| — |
|
IPR&D impairment |
|
| — |
|
|
| — |
|
|
| 2,430 |
|
|
| — |
|
Loss (gain) from equity securities, net |
|
| 392 |
|
|
| (69 | ) |
|
| 405 |
|
|
| 187 |
|
Non-GAAP income before income taxes |
| $ | 3,065 |
|
| $ | 2,131 |
|
| $ | 1,798 |
|
| $ | 4,226 |
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions, except percentages and per share amounts) |
|
| 2024 |
|
|
| 2023 |
|
|
| 2024 |
|
|
| 2023 |
|
Income tax expense reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP income tax expense |
| $ | 438 |
|
| $ | 549 |
|
| $ | 123 |
|
| $ | 865 |
|
Income tax effect of non-GAAP adjustments: |
|
|
|
|
|
|
|
| ||||||||
Acquisition-related – amortization(1) |
|
| 121 |
|
|
| 120 |
|
|
| 242 |
|
|
| 227 |
|
Acquisition-related – other costs(2) |
|
| 7 |
|
|
| 5 |
|
|
| 37 |
|
|
| 8 |
|
Restructuring |
|
| 7 |
|
|
| — |
|
|
| 16 |
|
|
| — |
|
IPR&D impairment |
|
| — |
|
|
| — |
|
|
| 611 |
|
|
| — |
|
Loss (gain) from equity securities, net |
|
| 33 |
|
|
| 1 |
|
|
| (6 | ) |
|
| 1 |
|
Discrete and related tax charges(3) |
|
| (60 | ) |
|
| (227 | ) |
|
| (100 | ) |
|
| (256 | ) |
Non-GAAP income tax expense |
| $ | 546 |
|
| $ | 448 |
|
| $ | 923 |
|
| $ | 844 |
|
|
|
|
|
|
|
|
|
| ||||||||
Effective tax rate reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP effective tax rate |
|
| 21.4 | % |
|
| 34.6 | % |
|
| (5.1 | )% |
|
| 29.9 | % |
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(3) |
|
| (3.5 | )% |
|
| (13.5 | )% |
|
| 56.4 | % |
|
| (10.0 | )% |
Non-GAAP effective tax rate |
|
| 17.8 | % |
|
| 21.0 | % |
|
| 51.4 | % |
|
| 20.0 | % |
|
|
|
|
|
|
|
|
| ||||||||
Net income (loss) attributable to Gilead reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP net income (loss) attributable to Gilead |
| $ | 1,614 |
|
| $ | 1,045 |
|
| $ | (2,556 | ) |
| $ | 2,055 |
|
Acquisition-related – amortization(1) |
|
| 458 |
|
|
| 461 |
|
|
| 916 |
|
|
| 884 |
|
Acquisition-related – other costs(2) |
|
| 14 |
|
|
| 26 |
|
|
| 117 |
|
|
| 32 |
|
Restructuring |
|
| 14 |
|
|
| — |
|
|
| 68 |
|
|
| — |
|
IPR&D impairment |
|
| — |
|
|
| — |
|
|
| 1,819 |
|
|
| — |
|
Loss (gain) from equity securities, net |
|
| 359 |
|
|
| (70 | ) |
|
| 412 |
|
|
| 187 |
|
Discrete and related tax charges(3) |
|
| 60 |
|
|
| 227 |
|
|
| 100 |
|
|
| 256 |
|
Non-GAAP net income attributable to Gilead |
| $ | 2,519 |
|
| $ | 1,688 |
|
| $ | 874 |
|
| $ | 3,414 |
|
|
|
|
|
|
|
|
|
| ||||||||
Diluted earnings (loss) per share reconciliation: |
|
|
|
|
|
|
|
| ||||||||
GAAP diluted earnings (loss) per share |
| $ | 1.29 |
|
| $ | 0.83 |
|
| $ | (2.05 | ) |
| $ | 1.63 |
|
Acquisition-related – amortization(1) |
|
| 0.37 |
|
|
| 0.37 |
|
|
| 0.73 |
|
|
| 0.70 |
|
Acquisition-related – other costs(2) |
|
| 0.01 |
|
|
| 0.02 |
|
|
| 0.09 |
|
|
| 0.03 |
|
Restructuring |
|
| 0.01 |
|
|
| — |
|
|
| 0.05 |
|
|
| — |
|
IPR&D impairment |
|
| — |
|
|
| — |
|
|
| 1.46 |
|
|
| — |
|
Loss (gain) from equity securities, net |
|
| 0.29 |
|
|
| (0.06 | ) |
|
| 0.33 |
|
|
| 0.15 |
|
Discrete and related tax charges(3) |
|
| 0.05 |
|
|
| 0.18 |
|
|
| 0.08 |
|
|
| 0.20 |
|
Non-GAAP diluted earnings per share |
| $ | 2.01 |
|
| $ | 1.34 |
|
| $ | 0.70 |
|
| $ | 2.71 |
|
|
|
|
|
|
|
|
|
| ||||||||
Non-GAAP adjustment summary: |
|
|
|
|
|
|
|
| ||||||||
Cost of goods sold adjustments |
| $ | 579 |
|
| $ | 581 |
|
| $ | 1,157 |
|
| $ | 1,110 |
|
Research and development expenses adjustments |
|
| 16 |
|
|
| 30 |
|
|
| 133 |
|
|
| 38 |
|
IPR&D impairment adjustments |
|
| — |
|
|
| — |
|
|
| 2,430 |
|
|
| — |
|
Selling, general and administrative expenses adjustments |
|
| 26 |
|
|
| 1 |
|
|
| 106 |
|
|
| 2 |
|
Total non-GAAP adjustments to costs and expenses |
|
| 620 |
|
|
| 612 |
|
|
| 3,826 |
|
|
| 1,150 |
|
Other (income) expense, net adjustments |
|
| 392 |
|
|
| (69 | ) |
|
| 405 |
|
|
| 187 |
|
Total non-GAAP adjustments before income taxes |
|
| 1,012 |
|
|
| 543 |
|
|
| 4,231 |
|
|
| 1,338 |
|
Income tax effect of non-GAAP adjustments above |
|
| (168 | ) |
|
| (126 | ) |
|
| (900 | ) |
|
| (235 | ) |
Discrete and related tax charges(3) |
|
| 60 |
|
|
| 227 |
|
|
| 100 |
|
|
| 256 |
|
Total non-GAAP adjustments to net income attributable to Gilead |
| $ | 905 |
|
| $ | 644 |
|
| $ | 3,431 |
|
| $ | 1,358 |
|
______________________________ | |
(1) | Relates to amortization of acquired intangibles. |
(2) | Adjustments include integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s acquisitions of MYR GmbH, MiroBio, Ltd., Tmunity Therapeutics, Inc., XinThera, Inc. and CymaBay Therapeutics, Inc. |
(3) | Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. |
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2024 FULL-YEAR GUIDANCE(1) (unaudited) | ||||||
|
|
|
|
|
|
|
(in millions, except percentages and per share amounts) |
| Provided February 6, 2024 |
| Updated April 25, 2024 |
| Updated August 8, 2024 |
Projected product gross margin GAAP to non-GAAP reconciliation: |
|
|
|
|
|
|
GAAP projected product gross margin |
| 76.0% - 77.0% |
| 76.0% - 77.0% |
| 76.0% - 77.0% |
Acquisition-related expenses and restructuring expenses |
| ~ 9.0% |
| ~ 9.0% |
| ~ 9.0% |
Non-GAAP projected product gross margin |
| 85.0% - 86.0% |
| 85.0% - 86.0% |
| 85.0% - 86.0% |
|
|
|
|
|
|
|
Projected operating income GAAP to non-GAAP reconciliation: |
|
|
|
|
|
|
GAAP projected operating income |
| $8,700 - $9,200 |
| $1,900 - $2,400 |
| $2,100 - $2,500 |
IPR&D impairment, acquisition-related and restructuring expenses |
| ~ 2,500 |
| ~ 5,100 |
| ~ 5,100 |
Non-GAAP projected operating income |
| $11,200 - $11,700 |
| $7,000 - $7,500 |
| $7,200 - $7,600 |
|
|
|
|
|
|
|
Projected effective tax rate GAAP to non-GAAP reconciliation: |
|
|
|
|
|
|
GAAP projected effective tax rate |
| ~ 21% |
| ~ 65% |
| ~ 87% |
Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments |
| (~ 2%) |
| (~ 35%) |
| (~ 57%) |
Non-GAAP projected effective tax rate |
| ~ 19% |
| ~ 30% |
| ~ 30% |
|
|
|
|
|
|
|
Projected diluted EPS GAAP to non-GAAP reconciliation: |
|
|
|
|
|
|
GAAP projected diluted EPS |
| $5.15 - $5.55 |
| $0.10 - $0.50 |
| $0.00 - $0.30 |
IPR&D impairment, acquisition-related and restructuring expenses, fair value adjustments of equity securities and discrete and related tax adjustments |
| ~ 1.70 |
| ~ 3.35 |
| ~ 3.60 |
Non-GAAP projected diluted EPS |
| $6.85 - $7.25 |
| $3.45 - $3.85 |
| $3.60 - $3.90 |
________________________________ | |
(1) | Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. |
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) | ||||||||
|
| June 30, |
| December 31, | ||||
(in millions) |
|
| 2024 |
|
| 2023 | ||
Assets |
|
|
|
| ||||
Cash, cash equivalents and marketable debt securities |
| $ | 2,772 |
| $ | 8,428 | ||
Accounts receivable, net |
|
| 4,663 |
|
| 4,660 | ||
Inventories |
|
| 3,388 |
|
| 3,366 | ||
Property, plant and equipment, net |
|
| 5,346 |
|
| 5,317 | ||
Intangible assets, net |
|
| 22,832 |
|
| 26,454 | ||
Goodwill |
|
| 8,314 |
|
| 8,314 | ||
Other assets |
|
| 6,265 |
|
| 5,586 | ||
Total assets |
| $ | 53,579 |
| $ | 62,125 | ||
Liabilities and Stockholders’ Equity |
|
|
|
| ||||
Current liabilities |
| $ | 10,781 |
| $ | 11,280 | ||
Long-term liabilities |
|
| 24,602 |
|
| 28,096 | ||
Stockholders’ equity(1) |
|
| 18,197 |
|
| 22,749 | ||
Total liabilities and stockholders’ equity |
| $ | 53,579 |
| $ | 62,125 |
________________________________ | |
(1) | As of June 30, 2024 and December 31, 2023, there were 1,246 shares of common stock issued and outstanding. |
GILEAD SCIENCES, INC. SELECTED CASH FLOW INFORMATION (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions) |
|
| 2024 |
|
|
| 2023 |
|
|
| 2024 |
|
|
| 2023 |
|
Net cash provided by operating activities |
| $ | 1,325 |
|
| $ | 2,337 |
|
| $ | 3,544 |
|
| $ | 4,082 |
|
Net cash used in investing activities |
|
| (307 | ) |
|
| (483 | ) |
|
| (2,514 | ) |
|
| (1,309 | ) |
Net cash used in financing activities |
|
| (2,953 | ) |
|
| (1,101 | ) |
|
| (4,314 | ) |
|
| (2,507 | ) |
Effect of exchange rate changes on cash and cash equivalents |
|
| (11 | ) |
|
| 14 |
|
|
| (29 | ) |
|
| 26 |
|
Net change in cash and cash equivalents |
|
| (1,947 | ) |
|
| 768 |
|
|
| (3,313 | ) |
|
| 292 |
|
Cash and cash equivalents at beginning of period |
|
| 4,718 |
|
|
| 4,936 |
|
|
| 6,085 |
|
|
| 5,412 |
|
Cash and cash equivalents at end of period |
| $ | 2,772 |
|
| $ | 5,704 |
|
| $ | 2,772 |
|
| $ | 5,704 |
|
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions) |
|
| 2024 |
|
|
| 2023 |
|
|
| 2024 |
|
|
| 2023 |
|
Net cash provided by operating activities |
| $ | 1,325 |
|
| $ | 2,337 |
|
| $ | 3,544 |
|
| $ | 4,082 |
|
Capital expenditures |
|
| (130 | ) |
|
| (139 | ) |
|
| (235 | ) |
|
| (248 | ) |
Free cash flow(1) |
| $ | 1,195 |
|
| $ | 2,199 |
|
| $ | 3,309 |
|
| $ | 3,834 |
|
________________________________ | |
(1) | Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above. |
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions) |
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 | ||||
HIV |
|
|
|
|
|
|
|
| ||||||||
Biktarvy – U.S. |
| $ | 2,585 |
| $ | 2,439 |
| $ | 4,900 |
| $ | 4,600 | ||||
Biktarvy – Europe |
|
| 370 |
|
| 302 |
|
| 735 |
|
| 606 | ||||
Biktarvy – Rest of World |
|
| 277 |
|
| 237 |
|
| 542 |
|
| 449 | ||||
|
|
| 3,232 |
|
| 2,979 |
|
| 6,177 |
|
| 5,656 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Descovy – U.S. |
|
| 434 |
|
| 460 |
|
| 805 |
|
| 855 | ||||
Descovy – Europe |
|
| 25 |
|
| 25 |
|
| 51 |
|
| 50 | ||||
Descovy – Rest of World |
|
| 26 |
|
| 31 |
|
| 55 |
|
| 60 | ||||
|
|
| 485 |
|
| 516 |
|
| 911 |
|
| 965 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Genvoya – U.S. |
|
| 372 |
|
| 455 |
|
| 704 |
|
| 872 | ||||
Genvoya – Europe |
|
| 45 |
|
| 56 |
|
| 95 |
|
| 111 | ||||
Genvoya – Rest of World |
|
| 23 |
|
| 29 |
|
| 44 |
|
| 58 | ||||
|
|
| 440 |
|
| 540 |
|
| 843 |
|
| 1,041 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Odefsey – U.S. |
|
| 233 |
|
| 267 |
|
| 457 |
|
| 497 | ||||
Odefsey – Europe |
|
| 72 |
|
| 74 |
|
| 148 |
|
| 149 | ||||
Odefsey – Rest of World |
|
| 10 |
|
| 11 |
|
| 21 |
|
| 22 | ||||
|
|
| 315 |
|
| 351 |
|
| 626 |
|
| 668 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Symtuza - Revenue share(1) – U.S. |
|
| 131 |
|
| 84 |
|
| 236 |
|
| 182 | ||||
Symtuza - Revenue share(1) – Europe |
|
| 34 |
|
| 33 |
|
| 67 |
|
| 70 | ||||
Symtuza - Revenue share(1) – Rest of World |
|
| 3 |
|
| 3 |
|
| 6 |
|
| 7 | ||||
|
|
| 168 |
|
| 120 |
|
| 309 |
|
| 259 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Other HIV(2) – U.S. |
|
| 65 |
|
| 74 |
|
| 125 |
|
| 136 | ||||
Other HIV(2) – Europe |
|
| 25 |
|
| 31 |
|
| 70 |
|
| 63 | ||||
Other HIV(2) – Rest of World |
|
| 15 |
|
| 15 |
|
| 27 |
|
| 28 | ||||
|
|
| 105 |
|
| 120 |
|
| 222 |
|
| 228 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Total HIV – U.S. |
|
| 3,821 |
|
| 3,778 |
|
| 7,226 |
|
| 7,142 | ||||
Total HIV – Europe |
|
| 571 |
|
| 521 |
|
| 1,167 |
|
| 1,049 | ||||
Total HIV – Rest of World |
|
| 353 |
|
| 326 |
|
| 695 |
|
| 624 | ||||
|
|
| 4,745 |
|
| 4,626 |
|
| 9,088 |
|
| 8,816 | ||||
Liver Disease |
|
|
|
|
|
|
|
| ||||||||
Sofosbuvir / Velpatasvir(3) – U.S. |
|
| 267 |
|
| 223 |
|
| 515 |
|
| 427 | ||||
Sofosbuvir / Velpatasvir(3) – Europe |
|
| 84 |
|
| 84 |
|
| 163 |
|
| 174 | ||||
Sofosbuvir / Velpatasvir(3) – Rest of World |
|
| 126 |
|
| 90 |
|
| 203 |
|
| 181 | ||||
|
|
| 476 |
|
| 397 |
|
| 881 |
|
| 782 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Vemlidy – U.S. |
|
| 117 |
|
| 96 |
|
| 212 |
|
| 183 | ||||
Vemlidy – Europe |
|
| 11 |
|
| 10 |
|
| 22 |
|
| 19 | ||||
Vemlidy – Rest of World |
|
| 115 |
|
| 113 |
|
| 233 |
|
| 216 | ||||
|
|
| 243 |
|
| 219 |
|
| 467 |
|
| 418 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Other Liver Disease(4) – U.S. |
|
| 47 |
|
| 37 |
|
| 89 |
|
| 64 | ||||
Other Liver Disease(4) – Europe |
|
| 47 |
|
| 37 |
|
| 94 |
|
| 78 | ||||
Other Liver Disease(4) – Rest of World |
|
| 19 |
|
| 21 |
|
| 38 |
|
| 44 | ||||
|
|
| 113 |
|
| 95 |
|
| 221 |
|
| 186 | ||||
Total Liver Disease – U.S. |
|
| 431 |
|
| 356 |
|
| 816 |
|
| 674 | ||||
Total Liver Disease – Europe |
|
| 142 |
|
| 131 |
|
| 279 |
|
| 271 | ||||
Total Liver Disease – Rest of World |
|
| 259 |
|
| 225 |
|
| 474 |
|
| 441 | ||||
|
|
| 832 |
|
| 711 |
|
| 1,569 |
|
| 1,386 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Veklury |
|
|
|
|
|
|
|
| ||||||||
Veklury – U.S. |
|
| 76 |
|
| 97 |
|
| 391 |
|
| 349 | ||||
Veklury – Europe |
|
| 53 |
|
| 52 |
|
| 123 |
|
| 163 | ||||
Veklury – Rest of World |
|
| 85 |
|
| 107 |
|
| 255 |
|
| 317 | ||||
|
|
| 214 |
|
| 256 |
|
| 769 |
|
| 829 | ||||
|
|
|
|
|
|
|
|
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in millions) |
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 | ||||
Oncology |
|
|
|
|
|
|
|
| ||||||||
Cell Therapy |
|
|
|
|
|
|
|
| ||||||||
Tecartus – U.S. |
|
| 63 |
|
| 56 |
|
| 118 |
|
| 114 | ||||
Tecartus – Europe |
|
| 37 |
|
| 29 |
|
| 73 |
|
| 56 | ||||
Tecartus – Rest of World |
|
| 7 |
|
| 4 |
|
| 16 |
|
| 6 | ||||
|
|
| 107 |
|
| 88 |
|
| 207 |
|
| 177 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Yescarta – U.S. |
|
| 186 |
|
| 217 |
|
| 357 |
|
| 427 | ||||
Yescarta – Europe |
|
| 169 |
|
| 133 |
|
| 327 |
|
| 254 | ||||
Yescarta – Rest of World |
|
| 58 |
|
| 30 |
|
| 110 |
|
| 58 | ||||
|
|
| 414 |
|
| 380 |
|
| 794 |
|
| 739 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Total Cell Therapy – U.S. |
|
| 250 |
|
| 272 |
|
| 475 |
|
| 542 | ||||
Total Cell Therapy – Europe |
|
| 206 |
|
| 162 |
|
| 400 |
|
| 310 | ||||
Total Cell Therapy – Rest of World |
|
| 66 |
|
| 34 |
|
| 126 |
|
| 65 | ||||
|
|
| 521 |
|
| 469 |
|
| 1,001 |
|
| 916 | ||||
Trodelvy |
|
|
|
|
|
|
|
| ||||||||
Trodelvy – U.S. |
|
| 224 |
|
| 189 |
|
| 429 |
|
| 351 | ||||
Trodelvy – Europe |
|
| 69 |
|
| 53 |
|
| 137 |
|
| 107 | ||||
Trodelvy – Rest of World |
|
| 26 |
|
| 17 |
|
| 62 |
|
| 23 | ||||
|
|
| 320 |
|
| 260 |
|
| 628 |
|
| 482 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Total Oncology – U.S. |
|
| 474 |
|
| 462 |
|
| 904 |
|
| 893 | ||||
Total Oncology – Europe |
|
| 275 |
|
| 215 |
|
| 537 |
|
| 417 | ||||
Total Oncology – Rest of World |
|
| 92 |
|
| 51 |
|
| 188 |
|
| 88 | ||||
|
|
| 841 |
|
| 728 |
|
| 1,629 |
|
| 1,398 | ||||
Other |
|
|
|
|
|
|
|
| ||||||||
AmBisome – U.S. |
|
| 17 |
|
| 20 |
|
| 31 |
|
| 27 | ||||
AmBisome – Europe |
|
| 69 |
|
| 69 |
|
| 139 |
|
| 129 | ||||
AmBisome – Rest of World |
|
| 65 |
|
| 61 |
|
| 124 |
|
| 111 | ||||
|
|
| 151 |
|
| 151 |
|
| 294 |
|
| 267 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Other(5) – U.S. |
|
| 98 |
|
| 64 |
|
| 156 |
|
| 127 | ||||
Other(5) – Europe |
|
| 8 |
|
| 10 |
|
| 18 |
|
| 22 | ||||
Other(5) – Rest of World |
|
| 24 |
|
| 17 |
|
| 36 |
|
| 26 | ||||
|
|
| 130 |
|
| 92 |
|
| 209 |
|
| 175 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Total Other – U.S. |
|
| 115 |
|
| 85 |
|
| 188 |
|
| 153 | ||||
Total Other – Europe |
|
| 77 |
|
| 80 |
|
| 156 |
|
| 152 | ||||
Total Other – Rest of World |
|
| 88 |
|
| 78 |
|
| 160 |
|
| 137 | ||||
|
|
| 280 |
|
| 243 |
|
| 504 |
|
| 442 | ||||
|
|
|
|
|
|
|
|
| ||||||||
Total product sales – U.S. |
|
| 4,916 |
|
| 4,777 |
|
| 9,525 |
|
| 9,211 | ||||
Total product sales – Europe |
|
| 1,118 |
|
| 999 |
|
| 2,262 |
|
| 2,052 | ||||
Total product sales – Rest of World |
|
| 878 |
|
| 788 |
|
| 1,772 |
|
| 1,607 | ||||
|
| $ | 6,912 |
| $ | 6,564 |
| $ | 13,559 |
| $ | 12,870 |
______________________________ | |
(1) | Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company. |
(2) | Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost. |
(3) | Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). |
(4) | Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi. |
(5) | Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig. |
Last Trade: | US$89.51 |
Daily Change: | 1.22 1.38 |
Daily Volume: | 5,291,053 |
Market Cap: | US$110.990B |
October 31, 2024 October 09, 2024 October 07, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB